Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:45:22 EST Tue 03 Nov 2026
Enter Symbol
or Name
USA
CA



Q:IBIO - IBIO INC - https://www.ibioinc.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IBIO - Q0.20.81·0.82170.40.8207+0.02082.663.5382350.80  0.8359  0.79023.82  0.685911:24:45Nov 0215 min RT 2¢

Recent Trades - Last 10 of 235
Time ETExPriceChangeVolume
11:24:45Q0.82180.021926
11:24:43Q0.82170.02184
11:22:54Q0.81770.01782
11:22:53Q0.81940.01951
11:22:06Q0.81950.019610
11:22:06Q0.81910.01926
11:22:06Q0.81890.01918
11:21:40Q0.82070.0208100
11:20:53Q0.820.0201100
11:20:53Q0.820.020180

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-11-02 16:30U:IBIONews ReleaseiBio to Participate in Upcoming Investor Conferences
2026-10-13 07:00U:IBIONews ReleaseiBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 Therapy
2026-09-01 16:30U:IBIONews ReleaseiBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
2026-08-28 07:00U:IBIONews ReleaseiBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-08-04 07:00U:IBIONews ReleaseiBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
2026-07-01 07:00U:IBIONews ReleaseiBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
2026-06-02 16:01U:IBIONews ReleaseiBio to Participate in Upcoming Healthcare Investor Conferences
2026-06-02 07:00U:IBIONews ReleaseiBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
2026-05-12 16:05U:IBIONews ReleaseiBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-05-08 07:15U:IBIONews ReleaseiBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
2026-04-08 07:00U:IBIONews ReleaseiBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
2026-03-16 16:30U:IBIONews ReleaseiBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
2026-03-09 07:00U:IBIONews ReleaseiBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
2026-02-24 07:00U:IBIONews ReleaseiBio to Participate in Upcoming Investor Conferences
2026-02-10 16:05U:IBIONews ReleaseiBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-01-09 07:00U:IBIONews ReleaseiBio Announces $26 Million Private Placement
2025-11-24 16:15U:IBIONews ReleaseiBio to Participate in the 8th Annual Evercore Healthcare Conference
2025-11-12 16:01U:IBIONews ReleaseiBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update